Business
MediPharm Labs Enters Landmark Commercial Agreement with Laboratório Teuto in Brazil
MediPharm Labs Enters Landmark Commercial Agreement with Laboratório Teuto in Brazil ...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"\n\n\n\n MediPharm Labs Enters Landmark Commercial Agreement with Laboratório Teuto in Brazil\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; BORDER-BOTTOM:black 0pt; BORDER-LEFT:black 0pt\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n MediPharm Labs expands its Brazilian presence where the medical cannabis market is estimated to be worth\n \n $198 million\n \n in 2024, serving over 670,000 patients.\n \n 1\n \n\n\n Products include full-spectrum, GMP sublingual oral solutions with extensive pharmaceutical validation and characterization.\n \n\n Teuto is one of\n \n Brazil's\n \n largest pharmaceutical manufacturers of both generic and branded medicines, with an extensive portfolio of oncologic specialty drugs, making it an ideal partner for MediPharm.\n \n\n\n\n\n BARRIE, ON\n \n\n ,\n \n\n Jan. 8, 2025\n \n\n /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (\"MediPharm\" or the \"Company\"), a leader in pharmaceutical-grade cannabis manufacturing, is proud to announce a commercial agreement with Laboratório Teuto (\"Teuto\"), a leading pharmaceutical manufacturer and marketer in\n \n Brazil\n \n . This partnership signifies a significant milestone as MediPharm expands its reach into one of the most tightly regulated medical cannabis markets globally.\n \n\n\n\n\n\n\n\n\n\n ANVISA Product Approval Marks Commercial Milestone Achievement\n \n\n\n ANVISA (Agência Nacional de Vigilância Sanitária) granted Teuto Sanitary Authorizations for two products manufactured by Medipharm. The approvals, published on\n \n December 30, 2024\n \n , mark the culmination of a rigorous process that underscores MediPharm's commitment to compliance, quality, and innovation in the global medical cannabis space. MediPharm and Teuto have been working closely together on the ANVISA approvals, whi...